HTA and HIV: The Case of Dual NRTI Backbones in the Italian Setting.
HIV
HTA
Italy
dual NRTI backbones
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
03 12 2020
03 12 2020
Historique:
received:
14
10
2020
revised:
30
11
2020
accepted:
02
12
2020
entrez:
8
12
2020
pubmed:
9
12
2020
medline:
3
2
2021
Statut:
epublish
Résumé
The aim of this study is to analyze the potential advantages of emtricitabine/tenofovir alafenamide (FTC/TAF) introduction, creating evidence-based information to orient strategies to reduce costs, thus preserving effectiveness and appropriateness. An Health Technology Assessment (HTA) was implemented in the years 2017-2018 comparing the dual backbones available in the Italian market: FTC/TAF, FTC/TDF (tenofovir disoproxil fumarate/emtricitabine) and ABC/3TC (abacavir/lamivudine). From an efficacy point of view, FTC/TAF ensured a higher percentage of virologic control and a better safety impact than FTC/TDF (improving the renal and bone safety profile, as well as the lipid picture). From an economic point of view, the results revealed a 4% cost saving for the Italian National Healthcare Service NHS with FTC/TAF introduction compared with the baseline scenario. Qualitative perceptions' results showed that FTC/TAF would decrease the burden of adverse events management, increasing the accessibility of patients to healthcare providers (FTC/TAF: 0.95, FTC/TDF: 0.10, ABC/3TC: 0.28;
Identifiants
pubmed: 33287274
pii: ijerph17239010
doi: 10.3390/ijerph17239010
pmc: PMC7729444
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Drug Combinations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Lancet HIV. 2016 Apr;3(4):e158-65
pubmed: 27036991
BMC Health Serv Res. 2018 Dec 3;18(1):914
pubmed: 30509286
BMC Med Inform Decis Mak. 2007 Jun 15;7:16
pubmed: 17573961
Int J Technol Assess Health Care. 2014 Jan;30(1):105-12
pubmed: 24451150
Allergy. 2009 May;64(5):669-77
pubmed: 19210357
Clinicoecon Outcomes Res. 2012;4:193-200
pubmed: 22888265
Value Health. 2007 Sep-Oct;10(5):336-47
pubmed: 17888098
Lancet Infect Dis. 2018 Mar;18(3):e76-e86
pubmed: 29066132
Lancet. 2015 Jun 27;385(9987):2606-15
pubmed: 25890673
Int J Technol Assess Health Care. 2010 Jul;26(3):309-16
pubmed: 20584360
Lancet HIV. 2017 May;4(5):e195-e204
pubmed: 28259777
J Acquir Immune Defic Syndr. 2013 May 1;63(1):96-100
pubmed: 23392460
Lancet HIV. 2017 May;4(5):e205-e213
pubmed: 28259776
Int J Technol Assess Health Care. 2008 Summer;24(3):244-58; discussion 362-8
pubmed: 18601792
J Infect Dis. 2011 Oct 15;204(8):1191-201
pubmed: 21917892
Lancet Infect Dis. 2016 Jan;16(1):43-52
pubmed: 26538525
Health Econ Rev. 2020 Aug 29;10(1):27
pubmed: 32860539
J Antimicrob Chemother. 2014 Dec;69(12):3169-80
pubmed: 25074854
J Med Internet Res. 2011 Sep 28;13(3):e72
pubmed: 21955510
Drugs. 2016 Jun;76(9):957-68
pubmed: 27189707
HIV Med. 2016 May;17 Suppl 2:4-16
pubmed: 26952360
BMC Health Serv Res. 2011 Jul 14;11:169
pubmed: 21756357
J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):211-7
pubmed: 21546850
PLoS One. 2016 Dec 28;11(12):e0168399
pubmed: 28030621
Lancet. 2008 Jul 26;372(9635):293-9
pubmed: 18657708
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):498-505
pubmed: 22205438
Lancet. 2010 Jul 3;376(9734):49-62
pubmed: 20609987
Int J Technol Assess Health Care. 2017 Jan;33(2):288-296
pubmed: 28578752